Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfamethizole
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sulfamethizole is a sulfonamide antibiotic used to treat a variety of susceptible bacterial infections. It acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase (also called dihydropteroate synthetase), thereby preventing the incorporation of para-aminobenzoic acid (PABA) into folic acid. This inhibition disrupts folic acid synthesis in bacteria—a process essential for DNA and protein synthesis—resulting in bacteriostatic activity. Sulfamethizole is primarily administered orally and is widely distributed throughout body tissues and fluids. It belongs to the class of short-acting sulfonamide antibiotics[1][2].
- Brand names
- Urobiotic
02
Targets
DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on sulfamethizole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfamethizole.